The science of rheumatoid arthritis: a prelude

Por Smolen, Josef S
Publicado em 2005

Expanding the frontiers of therapy

Por Smolen, Josef S
Publicado em 2006

Therapy of systemic lupus erythematosus: a look into the future

Por Smolen, Josef S
Publicado em 2002

SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus

Por Aringer, Martin, Smolen, Josef S
Publicado em 2003

The role of tumor necrosis factor-alpha in systemic lupus erythematosus

Por Aringer, Martin, Smolen, Josef S
Publicado em 2008

Developments in the clinical understanding of rheumatoid arthritis

Por Smolen, Josef S, Aletaha, Daniel
Publicado em 2009

Infliximab: 12 years of experience

Por Smolen, Josef S, Emery, Paul
Publicado em 2011

Autoantibodies in rheumatoid arthritis and their clinical significance

Por Steiner, Günter, Smolen, Josef
Publicado em 2002

Correction: Interleukin-6: a new therapeutic target

Por Smolen, Josef S, Maini, Ravinder N
Publicado em 2006

Interleukin-6: a new therapeutic target

Por Smolen, Josef S, Maini, Ravinder N
Publicado em 2006

Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor

Por Tan, Eng M., Smolen, Josef S.
Publicado no J Exp Med (2016)

The role of osteoprotegerin in arthritis

Por Schett, Georg, Redlich, Kurt, Smolen, Josef S
Publicado em 2003

Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs

Por Radner, Helga, Smolen, Josef S, Aletaha, Daniel
Publicado em 2014

Response to ‘Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis’

Por Vastesaeger, Nathan, Fautrel, Bruno, Smolen, Josef
Publicado no Arthritis Res Ther (2015)

Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials

Por Aletaha, Daniel, Alasti, Farideh, Smolen, Josef S.
Publicado no Arthritis Res Ther (2015)

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruct...

Por Smolen, Josef S, Avila, José C Martinez, Aletaha, Daniel
Publicado em 2011

Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients

Por Radner, Helga, Alasti, Farideh, Smolen, Josef S., Aletaha, Daniel
Publicado no Arthritis Res Ther (2015)

The stressed synovium

Por Schett, Georg, Tohidast-Akrad, Makiyeh, Steiner, Günter, Smolen, Josef
Publicado em 2001

Listeria-Associated Arthritis in a Patient Undergoing Etanercept Therapy: Case Report and Review of the Literature

Por Schett, Georg, Herak, Petra, Graninger, Winfried, Smolen, Josef S., Aringer, Martin
Publicado em 2005

Imbalance of local bone metabolism in inflammatory arthritis and its reversal upon tumor necrosis factor blockade: direct analysis of bone turnover in murine arthritis

Por Zwerina, Jochen, Tuerk, Birgit, Redlich, Kurt, Smolen, Josef S, Schett, Georg
Publicado em 2006